GlassScriptPhysician profile
Kelly L Cole
NPI 1124092234
$9,034.23
in general payments reported to CMS, 2019-2025
30 companies · $53.18 in 2025
The $53.18 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,969 · 2020: $642 · 2021: $301 · 2022: $821 · 2023: $2,254 · 2024: $1,994 · 2025: $53.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,231 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,230.90 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,822.56 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $1,204.45 | 2019-2024 | |
| Abbvie INC. | $1,182.22 | 2019-2024 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $855.87 | 2019-2025 | |
| Janssen Biotech, INC. | $725.16 | 2019-2024 | Tremfya, Remicade, Stelara |
| Ucb, INC. | $655.49 | 2019-2024 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.31 | 2019-2024 | Ofev, Cyltezo |
| Lilly USA, LLC | $300.06 | 2020-2024 | Taltz |
| Glaxosmithkline, LLC. | $279.62 | 2019-2024 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $211.20 | 2022-2024 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $174.89 | 2023-2024 | Acthar |
| Genentech USA, INC. | $164.59 | 2019-2023 | Actemra |
| Regeneron Healthcare Solutions, INC. | $138.44 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $119.28 | 2019-2024 | Orencia |
| Janssen Scientific Affairs, LLC | $110.71 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $77.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $72.38 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $68.48 | 2023 | Idacio |
| Aurinia Pharma U.S., INC. | $67.05 | 2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $67.02 | 2022-2024 | Strensiq |
| Horizon Therapeutics Plc | $66.30 | 2020-2023 | |
| Organon LLC | $60.01 | 2022-2024 | Hadlima, Renflexis |
| Radius Health, INC. | $45.44 | 2020-2024 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $45.23 | 2020-2021 | |
| Sandoz INC. | $44.12 | 2023 | Hyrimoz |
| Sobi, INC | $25.49 | 2024 | |
| Antares Pharma, INC. | $24.58 | 2020 | |
| Octapharma USA, INC. | $21.77 | 2023 | Octagam Immune Globulin (Human) |
| Pacira Pharmaceuticals Incorporated | $21.02 | 2023 | Zilretta, Iovera |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.